Frontiers | Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey (Saimiri Boliviensis Boliviensis)
Frontiers | S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes
Toll-Like Receptor 9 Agonists in Cancer | OTT
Injection Route and TLR9 Agonist Addition Significantly Impact Heroin Vaccine Efficacy | Molecular Pharmaceutics
Therapeutic Applications of Synthetic CpG Oligodeoxynucleotides as TLR9 Agonists for Immune Modulation | SpringerLink
Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen | Bioconjugate Chemistry
Full article: CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy
A CpG Oligonucleotide Can Protect Mice from a Low Aerosol Challenge Dose of Burkholderia mallei | Infection and Immunity
PDF) CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B� HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study
Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway
Cancers | Free Full-Text | Cancer Vaccination against Extracellular Vimentin Efficiently Adjuvanted with Montanide ISA 720/CpG
Human TLR9 Agonist Kit | Stimulatory CpG ODNs | InvivoGen
PDF) CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B� HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study
A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious Diseases | SpringerLink
PDF) CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B� HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study
A CpG Oligonucleotide Can Protect Mice from a Low Aerosol Challenge Dose of Burkholderia mallei | Infection and Immunity
Frontiers | Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade
TLR9-ERK-mTOR signaling is critical for autophagic cell death induced by CpG oligodeoxynucleotide 107 combined with irradiation in glioma cells | Scientific Reports
Synthetic CpG-ODN rapidly enriches immune compartments in neonatal chicks to induce protective immunity against bacterial infections | Scientific Reports
Targeting TLR9 agonists to secondary lymphoid organs induces potent immune responses against HBV infection - ScienceDirect
